NEK2 and familial pancreatic carcinoma: Consequently, while further preclinical studies and clinical trials are warranted for demonstration, NEK2 is nevertheless a promising target for pancreatic cancer therapy, and the combinatorial inhibition of NEK2 and PD-L1 will synergistically benefit pancreatic cancer patients.